Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02096042 · ClinicalTrials.gov registry record · Phase 1
Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT02096042: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT02096042 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02096042, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This clinical research study is made up of 3 phases: a Pilot Phase, Phase 1, and Phase 2. The goal of the Pilot Phase is to learn how safe it is to give the study drug brentuximab vedotin to patients with AML. The goal of Phase 1 is to learn more about the safety of the combination of brentuximab vedotin with azacytidine. The goal of Phase 2 is to learn if the combination of brentuximab vedotin and azacytidine can help to control AML.
Primary Outcome
MTD defined as maximum dose at which \<33% of patients experience a dose-limiting toxicity (DLT) during cycle 1.
Interventions
- DRUG Brentuximab Vedotin
- DRUG 5-Azacytidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2014-04 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
Why NCT02096042 stopped before completion
NCT02096042 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Brentuximab Vedotin is the first listed.
NCT02096042 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02096042 about?
NCT02096042 is a clinical study titled "Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)". This clinical research study is made up of 3 phases: a Pilot Phase, Phase 1, and Phase 2. The goal of the Pilot Phase is to learn how safe it is to give the study drug brentuximab vedotin to patients with AML. The goal of Phase 1 is to learn more about the safety of the combination of brentuximab v...
What is the current status of trial NCT02096042?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2014-04. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02096042?
The interventions under investigation include: Brentuximab Vedotin (DRUG), 5-Azacytidine (DRUG).
Who is sponsoring clinical trial NCT02096042?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02096042's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia